CA
LFCR icon

Clearstead Advisors’s Lifecore Biomedical LFCR Stock Holding History

Clearstead Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53 Buy
+10
New +$50 ﹤0.01% 3471

Other funds holding LFCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CA
CWC Advisors Lake Oswego, Oregon $225M AUM 23.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DT
DBA Trading Fort Lauderdale, Florida $199M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Clearstead Advisors's LFCR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 10 shares worth $53. The stake represents ﹤0.01% of the portfolio and ranks #3471 among its holdings.

32 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Clearstead Advisors held 10 shares of Lifecore Biomedical worth $53 as of Q2 2026.
  • Lifecore Biomedical was a new Clearstead Advisors position in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3471 holding.
  • 32 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.